Medtech startup Agatsa has raised Rs 12.5 crore from angel investors as it looks to grow its business operations and expand the product line.

This round of funding saw participation from well-known personalities from the healthcare industry, especially in the cardiac care segment. Now, Agatsa will look at expanding its reach into the B2B segment through tie-ups with hospitals and telehealth having made its presence in B2C.

 The ‘Made In India’ MedTech company aims to revolutionize the cardiac care industry in India. Agatsa has innovated the pocket 12-Lead ECG device which is 99 percent accurate and is being used by both doctors and heart patients in India for quick diagnosis/detection of cardiac problems. The device is very simple to use, affordable and pocket-sized anyone can easily use it on the go.

SanketLife is Agatsa's main product, an Internet of Things (IoT) p#latform that includes a portable and touch-based ECG machine that has been developed to make heart health screening more accessible and inexpensive for everyone via a Smartphone app and a cloud platform.

In a joint statement, Agasta co-founders Neha and Rahul Rastogi said, “This is our fourth round of funding, and we intend to grow our footprints in international markets along with proliferating in the domestic market aggressively with this funding.”

Agatsa raises $1 million in A series of investment rounds spearheaded by IAN and the Government of India's Technology Development Board.